BR112014004560A2 - compostos e composições como inibidores de c-kit quinase - Google Patents
compostos e composições como inibidores de c-kit quinaseInfo
- Publication number
- BR112014004560A2 BR112014004560A2 BR112014004560A BR112014004560A BR112014004560A2 BR 112014004560 A2 BR112014004560 A2 BR 112014004560A2 BR 112014004560 A BR112014004560 A BR 112014004560A BR 112014004560 A BR112014004560 A BR 112014004560A BR 112014004560 A2 BR112014004560 A2 BR 112014004560A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- kinase inhibitors
- compositions
- kit
- pdgfr
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 101150093908 PDGFRB gene Proteins 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
resumo patente de invenção: "compostos e composições como inibidores de c-kit quinase". a invenção refere-se a compostos de fórmula (i) e (ii) e a composições farmacêuticas dos mesmos, que são úteis como inibidores de proteína quinase, bem como métodos para usar tais compostos para tratar, melhorar ou prevenir uma condição associada à atividade de quinase anormal ou desregulada. em algumas modalidades, a invenção fornece métodos para usar tais compostos para tratar, melhorar ou prevenir doenças ou distúrbios que envolvem ativação anormal de c-kit ou c-kit e pdgfr (pdgfr?, pdgfr?) quinases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530038P | 2011-09-01 | 2011-09-01 | |
| PCT/US2012/052802 WO2013033167A1 (en) | 2011-09-01 | 2012-08-29 | Compounds and compositions as c-kit kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014004560A2 true BR112014004560A2 (pt) | 2017-04-04 |
Family
ID=46829904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014004560A BR112014004560A2 (pt) | 2011-09-01 | 2012-08-29 | compostos e composições como inibidores de c-kit quinase |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8569283B2 (pt) |
| EP (1) | EP2751104B1 (pt) |
| JP (1) | JP6134319B2 (pt) |
| KR (1) | KR101962495B1 (pt) |
| CN (1) | CN103797011B (pt) |
| AP (1) | AP2014007493A0 (pt) |
| AR (1) | AR087753A1 (pt) |
| AU (1) | AU2012302042B2 (pt) |
| BR (1) | BR112014004560A2 (pt) |
| CA (1) | CA2845169C (pt) |
| CL (1) | CL2014000492A1 (pt) |
| CO (1) | CO6900141A2 (pt) |
| CR (1) | CR20140107A (pt) |
| CU (1) | CU20140024A7 (pt) |
| EA (1) | EA026152B1 (pt) |
| ES (1) | ES2761332T3 (pt) |
| GT (1) | GT201400034A (pt) |
| IL (1) | IL231227A0 (pt) |
| MA (1) | MA35460B1 (pt) |
| MX (1) | MX339937B (pt) |
| PE (1) | PE20140909A1 (pt) |
| PH (1) | PH12014500372A1 (pt) |
| PL (1) | PL2751104T3 (pt) |
| PT (1) | PT2751104T (pt) |
| SG (1) | SG2014014369A (pt) |
| TN (1) | TN2014000068A1 (pt) |
| TW (1) | TW201313717A (pt) |
| UY (1) | UY34301A (pt) |
| WO (1) | WO2013033167A1 (pt) |
| ZA (1) | ZA201401175B (pt) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9199981B2 (en) * | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| AU2012302042B2 (en) | 2011-09-01 | 2016-03-31 | Novartis Ag | Compounds and compositions as c-kit kinase inhibitors |
| JP6387488B2 (ja) | 2013-01-10 | 2018-09-12 | プルモキネ、インコーポレイテッド | 非選択的キナーゼ阻害剤 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| CN106132403B (zh) | 2013-10-11 | 2020-04-28 | 普尔莫凯恩股份有限公司 | 喷雾干燥制剂 |
| US20150288928A1 (en) * | 2014-04-08 | 2015-10-08 | Sony Corporation | Security camera system use of object location tracking data |
| CN105384738B (zh) * | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| MX386598B (es) | 2015-07-02 | 2025-03-19 | Janssen Sciences Ireland Uc | Compuestos antibacterianos. |
| US10474987B2 (en) * | 2015-08-05 | 2019-11-12 | Whirlpool Corporation | Object recognition system for an appliance and method for managing household inventory of consumables |
| WO2017214413A1 (en) * | 2016-06-08 | 2017-12-14 | Chrysalis, Inc. | Imidazo[1,2-a]pyridine derivatives as histone demethylase inhibitors |
| CA3026010A1 (en) | 2016-06-16 | 2017-12-21 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| US20200308169A1 (en) | 2016-06-16 | 2020-10-01 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| EP3532063A4 (en) | 2016-10-27 | 2020-07-22 | Pulmokine, Inc. | POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION |
| US20180162291A1 (en) * | 2016-12-12 | 2018-06-14 | Wipro Limited | System and method of dynamically adjusting field of view of an image capturing device |
| EP4417262A3 (en) | 2017-03-01 | 2024-11-27 | Janssen Sciences Ireland Unlimited Company | Combination therapy |
| TWI798218B (zh) | 2017-05-02 | 2023-04-11 | 瑞士商諾華公司 | 組合療法 |
| WO2019090088A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| KR102625224B1 (ko) * | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CA3138123A1 (en) | 2019-05-13 | 2020-11-19 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| BR112021022685A2 (pt) * | 2019-05-13 | 2022-03-29 | Novartis Ag | Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4-oxadiazol-3-il)-2-metilfenil)imidazo[1,2-a]piridina-3-carboxamida |
| WO2021035788A1 (zh) | 2019-08-29 | 2021-03-04 | 中国科学院合肥物质科学研究院 | 吡唑衍生物及其用途 |
| BR112022003799A2 (pt) | 2019-09-13 | 2022-05-24 | Janssen Sciences Ireland Unlimited Co | Compostos antibacterianos |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US11767319B2 (en) | 2020-07-15 | 2023-09-26 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
| JP2023551434A (ja) | 2020-11-19 | 2023-12-08 | サード ハーモニック バイオ， インコーポレイテッド | 選択的ｃ－ｋｉｔキナーゼ阻害剤の医薬組成物ならびにその作製および使用のための方法 |
| AU2022237769A1 (en) | 2021-03-16 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN117580843A (zh) | 2021-03-17 | 2024-02-20 | 爱尔兰詹森科学公司 | 抗菌化合物 |
| BR112023018654A2 (pt) | 2021-03-17 | 2023-10-03 | Janssen Sciences Ireland Unlimited Co | Compostos antibacterianos |
| CN118159543A (zh) | 2021-10-28 | 2024-06-07 | 爱尔兰詹森科学公司 | 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物 |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| TW202430152A (zh) * | 2022-11-30 | 2024-08-01 | 美商纜圖藥品公司 | 野生型ｋｉｔ抑制劑 |
| WO2024124002A1 (en) * | 2022-12-07 | 2024-06-13 | Third Harmonic Bio, Inc. | Compounds and compositions as c-kit kinase inhibitors |
| WO2024123966A1 (en) * | 2022-12-07 | 2024-06-13 | Third Harmonic Bio, Inc. | Compounds and compositions as c-kit kinase inhibitors |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025072330A1 (en) * | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004001903A2 (en) | 2002-06-20 | 2003-12-31 | Beacon Looms, Inc. | Knitted electrical conductor fabric |
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP5184887B2 (ja) | 2004-09-09 | 2013-04-17 | ナトコ ファーマ リミテッド | ｂｃｒ−ａｂｌキナーゼの阻害剤としての新規フェニルアミノピリミジン誘導体 |
| JP5197016B2 (ja) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ， エルエルシー | 酵素モジュレータ及び治療 |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| KR20090075889A (ko) * | 2006-11-03 | 2009-07-09 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| AU2011329233A1 (en) * | 2010-11-15 | 2013-05-23 | Abbvie Deutschland Gmbh & Co Kg | NAMPT and ROCK inhibitors |
| US20130023751A1 (en) | 2011-07-18 | 2013-01-24 | Samuel Victor Lichtenstein | Water retention monitoring |
| JP2014525462A (ja) | 2011-09-01 | 2014-09-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｐｄｇｆｒキナーゼ阻害剤としての化合物および組成物 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| EA201490539A1 (ru) | 2011-09-01 | 2014-06-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов c-kit киназы |
| AU2012302042B2 (en) | 2011-09-01 | 2016-03-31 | Novartis Ag | Compounds and compositions as c-kit kinase inhibitors |
-
2012
- 2012-08-29 AU AU2012302042A patent/AU2012302042B2/en not_active Ceased
- 2012-08-29 CA CA2845169A patent/CA2845169C/en active Active
- 2012-08-29 BR BR112014004560A patent/BR112014004560A2/pt not_active Application Discontinuation
- 2012-08-29 AP AP2014007493A patent/AP2014007493A0/xx unknown
- 2012-08-29 EP EP12756885.5A patent/EP2751104B1/en active Active
- 2012-08-29 WO PCT/US2012/052802 patent/WO2013033167A1/en active Application Filing
- 2012-08-29 JP JP2014528537A patent/JP6134319B2/ja active Active
- 2012-08-29 US US13/598,213 patent/US8569283B2/en active Active
- 2012-08-29 SG SG2014014369A patent/SG2014014369A/en unknown
- 2012-08-29 UY UY34301A patent/UY34301A/es not_active Application Discontinuation
- 2012-08-29 PH PH1/2014/500372A patent/PH12014500372A1/en unknown
- 2012-08-29 PE PE2014000295A patent/PE20140909A1/es not_active Application Discontinuation
- 2012-08-29 CN CN201280042743.4A patent/CN103797011B/zh active Active
- 2012-08-29 MX MX2014002484A patent/MX339937B/es active IP Right Grant
- 2012-08-29 ES ES12756885T patent/ES2761332T3/es active Active
- 2012-08-29 PL PL12756885T patent/PL2751104T3/pl unknown
- 2012-08-29 EA EA201490545A patent/EA026152B1/ru not_active IP Right Cessation
- 2012-08-29 PT PT127568855T patent/PT2751104T/pt unknown
- 2012-08-29 KR KR1020147008107A patent/KR101962495B1/ko active Active
- 2012-08-31 TW TW101131942A patent/TW201313717A/zh unknown
- 2012-08-31 AR ARP120103223 patent/AR087753A1/es unknown
-
2013
- 2013-09-19 US US14/031,792 patent/US8754071B2/en active Active
-
2014
- 2014-02-17 ZA ZA2014/01175A patent/ZA201401175B/en unknown
- 2014-02-17 TN TNP2014000068A patent/TN2014000068A1/en unknown
- 2014-02-27 IL IL231227A patent/IL231227A0/en unknown
- 2014-02-27 GT GT201400034A patent/GT201400034A/es unknown
- 2014-02-27 CU CU20140024A patent/CU20140024A7/es unknown
- 2014-02-27 CL CL2014000492A patent/CL2014000492A1/es unknown
- 2014-02-28 CO CO14043417A patent/CO6900141A2/es unknown
- 2014-02-28 CR CR20140107A patent/CR20140107A/es unknown
- 2014-03-28 MA MA36864A patent/MA35460B1/fr unknown
- 2014-04-22 US US14/258,963 patent/US9023839B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014004560A2 (pt) | compostos e composições como inibidores de c-kit quinase | |
| BR112014004319A2 (pt) | compostos e composições como inibidores de c-kit cinase | |
| BR112014004465A2 (pt) | compostos e composições como inibidores de pdgfr cinase | |
| BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
| BR112014003963A2 (pt) | compostos e composições como inibidores de quinase c-kit | |
| MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
| NI201100166A (es) | Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| BR112012022513A2 (pt) | derivados de piperidin-4-il azetidina como inibidores de jak1 | |
| JO3002B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| BR112014030386A2 (pt) | compostos e composições para modular a atividade de egfr | |
| BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| BR112013032720A2 (pt) | "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados" | |
| MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| HK1210174A1 (zh) | 用於治療過度增殖性|疾病的絲氨酸/蘇氨酸激酶抑制劑 | |
| MD4556B1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| SV2009003212A (es) | Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct | |
| MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) |
|
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |